- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- January 2025
- 153 Pages
Global
From €5416EUR$5,950USD£4,600GBP
- Report
- May 2023
- 85 Pages
United States
From €5416EUR$5,950USD£4,600GBP
- Report
- September 2022
- 225 Pages
Global
From €6826EUR$7,500USD£5,798GBP
- Report
- June 2022
- 209 Pages
Global
From €3277EUR$3,600USD£2,783GBP
- Report
- January 2023
- 27 Pages
Global
€11150EUR$12,250USD£9,470GBP
Octagam is a brand of immune globulin intravenous (IGIV) therapy used to treat a variety of immune disorders. It is a sterile solution of human immunoglobulin G (IgG) derived from the pooled plasma of thousands of healthy donors. Octagam is used to treat primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and Kawasaki disease. It is also used to prevent infections in patients with hypogammaglobulinemia, a condition in which the body does not produce enough antibodies to fight off infections.
Octagam is a part of the larger immune disorders drugs market, which includes a variety of treatments for conditions that affect the body's ability to fight off infections. These treatments range from antibiotics to immunosuppressants to biologics. The market is highly competitive, with many companies offering similar products.
Some of the companies in the Octagam market include Grifols, CSL Behring, Kedrion, Biotest, Octapharma, and Shire. Show Less Read more